Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report From: Multiple Sclerosis News Today By: Alice Melao Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report Spherix Global Insights2018-09-24T15:38:12+00:00 Related Posts Biogen Drops After Piper Jaffray Downgrade, Price Target Cut June 28, 2019 Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition June 28, 2019 DMT Choice for Your MS Is Your Decision March 19, 2019 Ocrevus Predicted to Be a Billion-dollar Blockbuster September 4, 2018 Lupus Clinical Trials May Not Be Representative of Real-World Population, Report Suggests August 1, 2018
